Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Early antibody therapy can induce long-lasting immunity to SHIV.
Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies.
Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.